Exact Therapeutics AS
OSE:EXTX
Intrinsic Value
The intrinsic value of one EXTX stock under the Base Case scenario is 1.57 NOK. Compared to the current market price of 3 NOK, Exact Therapeutics AS is Overvalued by 48%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Exact Therapeutics AS
Loading...
Fundamental Analysis

Revenue & Expenses Breakdown
Exact Therapeutics AS
Balance Sheet Decomposition
Exact Therapeutics AS
Current Assets | 133.2m |
Cash & Short-Term Investments | 99.5m |
Receivables | 33.7m |
Non-Current Assets | 20m |
PP&E | 4.8m |
Other Non-Current Assets | 15.2m |
Free Cash Flow Analysis
Exact Therapeutics AS
NOK | |
Free Cash Flow | NOK |
Earnings Waterfall
Exact Therapeutics AS
Revenue
|
0
NOK
|
Operating Expenses
|
-51.4m
NOK
|
Operating Income
|
-51.4m
NOK
|
Other Expenses
|
-951.8k
NOK
|
Net Income
|
-52.3m
NOK
|
EXTX Profitability Score
Profitability Due Diligence
Exact Therapeutics AS's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Exact Therapeutics AS's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
EXTX Solvency Score
Solvency Due Diligence
Exact Therapeutics AS's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Exact Therapeutics AS's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EXTX Price Targets Summary
Exact Therapeutics AS
Dividends
Current shareholder yield for EXTX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one EXTX stock under the Base Case scenario is 1.57 NOK.
Compared to the current market price of 3 NOK, Exact Therapeutics AS is Overvalued by 48%.